566 results on '"Tullis, Elizabeth"'
Search Results
2. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
3. High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modification
4. Genomic epidemiology of Mycobacterium abscessus in a Canadian cystic fibrosis centre
5. Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease
6. The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations
7. The negative impact of chronic rhinosinusitis on the health-related quality of life among adult patients with cystic fibrosis
8. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
9. Burkholderia in Transplant: Important to Speciate and Important to Treat
10. SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium.
11. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis
12. Sleep breathing disorder frequency, risk factors, and treatment among adults with cystic fibrosis
13. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation
14. Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis
15. Cystic fibrosis–related diabetes onset can be predicted using biomarkers measured at birth
16. Lung transplantation for cystic fibrosis
17. ‘Go for it, dream big, work hard and persist’: A message to the next generation of CF leaders in recognition of International Women's Day 2020
18. The future of cystic fibrosis care: a global perspective
19. Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis
20. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis and at Least OneF508delAllele: 144-Week Interim Results From a 192-Week Open-label Extension Study
21. Factors associated with lung function response with oral antibiotic treatment of pulmonary exacerbations in cystic fibrosis
22. Pre-transplant factors associated with mortality after lung transplantation in cystic fibrosis: A systematic review and meta-analysis
23. Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His
24. Cystic Fibrosis-Related Diabetes Screening in Adults: A Gap Analysis and Evaluation of Accuracy of Glycated Hemoglobin Levels
25. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
26. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
27. Burkholderia in Transplant: Important to Speciate and Important to Treat
28. Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients
29. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
30. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations
31. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis
32. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients
33. Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass.
34. High-flow nasal oxygen versus noninvasive ventilation in adult patients with cystic fibrosis: a randomized crossover physiological study
35. Nasal potential difference: Best or average result for CFTR function as diagnostic criteria for cystic fibrosis?
36. Frailty predicts outcomes in cystic fibrosis patients listed for lung transplantation
37. Management of pregnancy in cystic fibrosis
38. Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update
39. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
40. Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
41. Functional integrity in children with anoxic brain injury from drowning
42. Cover Image
43. Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis
44. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients
45. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients
46. High Quality Phasing Using Linked-Read Whole Genome Sequencing of Patient Cohorts Informs Genetic Understanding of Complex Traits
47. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
48. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
49. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis
50. Fourier Transform Infrared Spectroscopy for Typing Burkholderia cenocepacia ET12 Isolates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.